Your browser doesn't support javascript.
loading
Analgesic tolerance and cross-tolerance to the bifunctional opioid/neuropeptide FF receptors agonist EN-9 and µ-opioid receptor ligands at the supraspinal level in mice.
Han, Zhenglan; Jin, Guofei; Tang, Jiancai; Wang, Hanyan; Guo, Dongmei; Zhang, Jingping.
Affiliation
  • Han Z; Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 55 Dongshun Road, Nanchong 637100, PR China.
  • Jin G; Nanchong Key Laboratory of Metabolic Drugs and Biological Products, 55 Dongshun Road, Nanchong 637100, PR China.
  • Tang J; Nanchong Key Laboratory of Metabolic Drugs and Biological Products, 55 Dongshun Road, Nanchong 637100, PR China.
  • Wang H; Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 55 Dongshun Road, Nanchong 637100, PR China.
  • Guo D; Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 55 Dongshun Road, Nanchong 637100, PR China.
  • Zhang J; Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 55 Dongshun Road, Nanchong 637100, PR China. Electronic address: zhangjingping@nsmc.edu.cn.
Neuropeptides ; 97: 102309, 2023 Feb.
Article in En | MEDLINE | ID: mdl-36410163
ABSTRACT
The chimeric peptide EN-9 was reported as a κ-opioid/neuropeptide FF receptors bifunctional agonist that modulated chronic pain with no tolerance. Many lines of evidence have shown that the effect of the κ-opioid receptor is mediated by not only its specific activation but also downstream events participation, especially interaction with the µ-opioid receptor pathway in antinociception and tolerance on most occasions. The present study investigated the acute and chronic cross-tolerance of EN-9 with µ-opioid receptor agonist EM-2, DAMGO, and morphine after intracerebroventricularly (i.c.v) injection in the mouse tail-flick test. In the acute tolerance test, EN-9 showed symmetrical acute cross-tolerance to DAMGO but no cross-tolerance to EM2. In the chronic tolerance test, EN-9 had no tolerance after eight days of repeated administration. However, EN-9 illustrated complete cross-tolerance to morphine and symmetrical cross-tolerance to EM2. In addition, inhibition of NPFF receptor could induce the tolerance development of EN-9. These findings indicated that supraspinal EN-9-induced antinociception contains additional components, which are mediated by the downstream µ-opioid receptor pathway both in acute and chronic treatment, whereas the subtypes of µ-opioid receptor or NPFF system pathway involved in antinociceptive effects induced by EN-9 are complex. Identifying the receptor mechanism could help design preferable bifunctional opioid compounds.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Analgesics / Analgesics, Opioid Type of study: Prognostic_studies Limits: Animals Language: En Journal: Neuropeptides Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Analgesics / Analgesics, Opioid Type of study: Prognostic_studies Limits: Animals Language: En Journal: Neuropeptides Year: 2023 Document type: Article